Quick Answer
Verrica Pharmaceuticals Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
Verrica Pharmaceuticals Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $30.98M | -27.7% |
| 2023 | $42.87M | — |
| 2022 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.62M | -50.1% | -12.0% |
| June 30, 2025 | $24.58M | -42.5% | -11.6% |
| March 31, 2025 | $27.81M | -35.1% | -10.2% |
| December 31, 2024 | $30.98M | -27.7% | -28.5% |
| September 30, 2024 | $43.30M | +2.1% | +1.3% |
| June 30, 2024 | $42.75M | — | -0.2% |
| March 31, 2024 | $42.85M | — | -0.1% |
| December 31, 2023 | $42.87M | — | +1.1% |
- Verrica Pharmaceuticals Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: